<DOC>
	<DOCNO>NCT02845804</DOCNO>
	<brief_summary>The objective study 1 . To establish prospective registry whole patient receive percutaneous coronary intervention Xience Xpedition™/Alpine™ stent 2 . To evaulate long-term efficacy safety coronary stenting Xience Xpedition™/Alpine™ stent 3 . To compare long-term efficacy safety coronary stenting Xience Xpedition™/Alpine ™ stent contemporary drug-eluting stent establish registry</brief_summary>
	<brief_title>Effect Efficacy Xpedition™/Alpine™ , Everolimus-eluting Stent Coronary Atherosclerosis</brief_title>
	<detailed_description>Secondary endpoint study Stent thrombosis-24 hour ( acute ) , 30 day ( subacute ) , 1 year ( late ) , every 1 year till 3 year ( very-late ) index PCI Target vessl failure Composite rate cardiac death MI , 3 year Composite rate death MI Composite rate death , MI , repeat revascularization Compliance therapy interruption prescribe adjunctive antiplatelet therapy</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient agree participate study sign informed consent form . Alternatively , legally authorize patient representative may agree patient 's participation study sign inform consent form There exclusion criterion registry .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>everolimus-eluting stent</keyword>
</DOC>